"krishna-prasad-chigurupati"

The drug firm plans to invest about Rs 180 crore on a Multiple Units Pellet System (MUPS) block, around Rs 250 crore on expanding active pharmaceutical ingredients (API) capacity.

Consolidated revenue from operations of the company stood at Rs 799 crore for the quarter under consideration

Granules India, Laurus Labs to set up new manufacturing facilities for finished dosages and formulations, respectively